Innovent Biologics (HK:1801) has released an update.
Innovent Biologics has decided to terminate its proposed subscription agreement with Fortvita and Lostrancos after receiving feedback from shareholders. The company remains committed to its strategic objectives and aims to focus on long-term international growth, believing that the termination is in the best interest of shareholders.
For further insights into HK:1801 stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
